human set 2 cell line (DSMZ)
Structured Review
Human Set 2 Cell Line, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 129 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+set+2+cell+line/SET-2/pm38646919-36-1-18
Average 94 stars, based on 129 article reviews
Images
Related Articles
Mutagenesis:Article Title: miR-146a -/- mice model reveals that NF-κB inhibition reverts inflammation-driven myelofibrosis-like phenotype. Article Snippet: Funding information Ministerio de Ciencia, Innovación y Universidades, Grant/Award Number: FPU18/03189; Next Generation EU, Grant/Award Number: PMP21/00052; Fundación Séneca, Grant/Award Number: 20644/JLI/18; Instituto de Salud Carlos III, Grant/Award Numbers: PI18/00316, PI20/00136, PI21/00347; UCAM, Grant/Award Numbers: GE/FE/14-21, GE/FE/15-23, GE/FE/14-24 Abstract Emerging evidence shows the crucial role of inflammation (particularly NF-κB pathway) in the development and progression of myelofibrosis (MF), becoming a promising therapeutic target.. Furthermore, tailoring treatment with currently available JAK inhibitors (such as ruxolitinib or fedratinib) does not modify the natural history of the disease and has important limitations, including cytopenias.. Since recent studies have highlighted the role of miR-146a, a negative regulator of the NF-κB pathway, in the pathogenesis of MF; here we used miR-146a / (KO) mice, a MF-like model lacking driver mutations, to investigate whether pharmacological inhibition of JAK/STAT and/or NF-κB pathways may reverse the myelofibrotic phenotype of these mice. |
